it is concluded that 4'-epi-doxorubicin is not superior to adriamycin in this low-prospect treatment area , but studies with increased doses appear necessary in adriamycin-sensitive tumors because of recent reports from phase-iii trials showing reduced cardiac and gastrointestinal toxicity with 4'-epi-doxorubicin in comparison with adriamycin .
C0014582
4
C0013089
doxorubicin